publication venue for
- Refining items for a preference-based, amyotrophic lateral sclerosis specific, health-related quality of life scale. 23:508-516. 2022
- Genetic testing for amyotrophic lateral sclerosis in Canada – an assessment of current practices. 23:305-312. 2022
- A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis. 20:584-594. 2019
- Author response to a Letter to the Editor entitled: Edaravone administration in pivotal clinical study 19 (Authors: Genge, Angela; Brooks, Benjamin). 20:300-302. 2019
- Is edaravone harmful? (A placebo is not a control). 19:477-482. 2018
- 50bp deletion in the promoter for superoxide dismutase 1 (SOD1) reduces SOD1 expression in vitro and may correlate with increased age of onset of sporadic amyotrophic lateral sclerosis. 9:229-237. 2008
- Evaluation of the Golgi trafficking protein VPS54 (wobbler) as a candidate for ALS. 9:141-148. 2008
- Screening of hypoxia-inducible genes in sporadic ALS. 9:299-305. 2008
- Lasting impact in families after death from ALS. 2:181-187. 2001